Long-term engraftment and maturation of autologous iPSC-derived cardiomyocytes in two rhesus macaques.
Cell Stem Cell
; 31(7): 974-988.e5, 2024 Jul 05.
Article
en En
| MEDLINE
| ID: mdl-38843830
ABSTRACT
Cellular therapies with cardiomyocytes produced from induced pluripotent stem cells (iPSC-CMs) offer a potential route to cardiac regeneration as a treatment for chronic ischemic heart disease. Here, we report successful long-term engraftment and in vivo maturation of autologous iPSC-CMs in two rhesus macaques with small, subclinical chronic myocardial infarctions, all without immunosuppression. Longitudinal positron emission tomography imaging using the sodium/iodide symporter (NIS) reporter gene revealed stable grafts for over 6 and 12 months, with no teratoma formation. Histological analyses suggested capability of the transplanted iPSC-CMs to mature and integrate with endogenous myocardium, with no sign of immune cell infiltration or rejection. By contrast, allogeneic iPSC-CMs were rejected within 8 weeks of transplantation. This study provides the longest-term safety and maturation data to date in any large animal model, addresses concerns regarding neoantigen immunoreactivity of autologous iPSC therapies, and suggests that autologous iPSC-CMs would similarly engraft and mature in human hearts.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Miocitos Cardíacos
/
Células Madre Pluripotentes Inducidas
/
Macaca mulatta
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Cell Stem Cell
/
Cell stem cell (Online)
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos